tiprankstipranks
Halozyme Therapeutics (CH:RV7)
:RV7

Halozyme (RV7) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Halozyme has a market cap or net worth of CHF9.45B. The enterprise value is $11.40K.
Market CapCHF9.45B
Enterprise Value$11.40K

Share Statistics

Halozyme has 113,498,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,498,000
Owned by Insiders0.94%
Owned by Institutions12.40%

Financial Efficiency

Halozyme’s return on equity (ROE) is 6.49 and return on invested capital (ROIC) is 23.59%.
Return on Equity (ROE)6.49
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)23.59%
Return on Capital Employed (ROCE)0.35
Revenue Per Employee3.30M
Profits Per Employee749.15K
Employee Count423
Asset Turnover0.55
Inventory Turnover1.73

Valuation Ratios

The current PE Ratio of Halozyme is 29.2. Halozyme’s PEG ratio is -1.04.
PE Ratio29.2
PS Ratio5.77
PB Ratio165.22
Price to Fair Value165.22
Price to FCF12.51
Price to Operating Cash Flow14.70
PEG Ratio-1.04

Income Statement

In the last 12 months, Halozyme had revenue of 1.40B and earned 316.89M in profits. Earnings per share was 2.64.
Revenue1.40B
Gross Profit1.09B
Operating Income816.29M
Pretax Income466.88M
Net Income316.89M
EBITDA573.05M
Earnings Per Share (EPS)2.64

Cash Flow

In the last 12 months, operating cash flow was 818.60M and capital expenditures -12.37M, giving a free cash flow of 806.22M billion.
Operating Cash Flow818.60M
Free Cash Flow806.22M
Free Cash Flow per Share7.10

Dividends & Yields

Halozyme pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.34
52-Week Price Change
50-Day Moving Average
200-Day Moving Average
Relative Strength Index (RSI)
Average Volume (3m)

Important Dates

Halozyme upcoming earnings date is Nov 9, 2026, After Close (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 9, 2026
Ex-Dividend Date

Financial Position

Halozyme as a current ratio of 4.66, with Debt / Equity ratio of 1495.48%
Current Ratio4.66
Quick Ratio3.66
Debt to Market Cap0.27
Net Debt to EBITDA3.51
Interest Coverage Ratio45.03

Taxes

In the past 12 months, Halozyme has paid 149.99M in taxes.
Income Tax149.99M
Effective Tax Rate0.32

Enterprise Valuation

Halozyme EV to EBITDA ratio is 17.58, with an EV/FCF ratio of 15.63.
EV to Sales7.21
EV to EBITDA17.58
EV to Free Cash Flow15.63
EV to Operating Cash Flow15.46

Balance Sheet

Halozyme has CHF231.00M in cash and marketable securities with CHF2.15B in debt, giving a net cash position of -CHF1.92B billion.
Cash & Marketable SecuritiesCHF231.00M
Total DebtCHF2.15B
Net Cash-CHF1.92B
Net Cash Per Share-CHF16.88
Tangible Book Value Per Share-CHF12.63

Margins

Gross margin is 78.18%, with operating margin of 58.45%, and net profit margin of 22.69%.
Gross Margin78.18%
Operating Margin58.45%
Pretax Margin33.43%
Net Profit Margin22.69%
EBITDA Margin41.03%
EBIT Margin34.73%

Analyst Forecast

The average price target for Halozyme is CHF75.82, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF75.82
Price Target Upside― Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast29.37%
EPS Growth Forecast-28.25%

Scores

Smart Score8
AI Score